JW Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company headquartered in Seoul, South Korea, focused on developing innovative therapeutics for central nervous system (CNS) disorders and other unmet medical needs. Founded in 1945, the company has evolved from a traditional pharmaceutical manufacturer into a modern biopharmaceutical company with a strong focus on neuroscience research and drug development[@pharmaceutical].
The company is listed on the Korea Exchange (KRX: 001060) and has positioned itself as one of the leading Korean pharmaceutical companies in the CNS disorder space, with multiple programs targeting Alzheimer's disease, Parkinson's disease, and other neurological conditions[@krx].
Company Overview
| Attribute | Details | |-----------|---------| | Founded | 1945 | | Headquarters | Seoul, South Korea | | Stock | KRX: 001060 | | CEO | Lee Byeol-jun | | Website | jwpharma.co.kr | | Employees | 2,000+ | | Revenue | ~$500 million annually | | Market | Korea, global export |
Corporate History
Founded in 1945, JW Pharmaceutical has grown to become one of Korea's established pharmaceutical companies:
1945: Company founded as Korean pharmaceutical manufacturer
1990s: Expansion into CNS therapeutics
2000s: Development of proprietary drug delivery technologies
2010s: Active CNS pipeline development for neurodegeneration
2020s: Advanced clinical trials for PD and AD programs
Business Segments
Pharmaceutical Products
...
Overview
JW Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company headquartered in Seoul, South Korea, focused on developing innovative therapeutics for central nervous system (CNS) disorders and other unmet medical needs. Founded in 1945, the company has evolved from a traditional pharmaceutical manufacturer into a modern biopharmaceutical company with a strong focus on neuroscience research and drug development[@pharmaceutical].
The company is listed on the Korea Exchange (KRX: 001060) and has positioned itself as one of the leading Korean pharmaceutical companies in the CNS disorder space, with multiple programs targeting Alzheimer's disease, Parkinson's disease, and other neurological conditions[@krx].
Company Overview
| Attribute | Details | |-----------|---------| | Founded | 1945 | | Headquarters | Seoul, South Korea | | Stock | KRX: 001060 | | CEO | Lee Byeol-jun | | Website | jwpharma.co.kr | | Employees | 2,000+ | | Revenue | ~$500 million annually | | Market | Korea, global export |
Corporate History
Founded in 1945, JW Pharmaceutical has grown to become one of Korea's established pharmaceutical companies:
1945: Company founded as Korean pharmaceutical manufacturer
1990s: Expansion into CNS therapeutics
2000s: Development of proprietary drug delivery technologies
2010s: Active CNS pipeline development for neurodegeneration
2020s: Advanced clinical trials for PD and AD programs
Business Segments
Pharmaceutical Products
JW Pharmaceutical manufactures and markets:
Prescription medications
Over-the-counter products
Generic pharmaceuticals
Biosimilars
Research and Development
The company's R&D focus areas include:
Novel small molecule therapeutics
Biologics development
Drug delivery systems
Fixed-dose combinations
Global Partnerships
JW Pharmaceutical collaborates with:
International pharmaceutical companies
Academic institutions
Contract research organizations
Neurodegeneration Pipeline
Parkinson's Disease Programs
| Drug | Mechanism | Stage | Status | |------|-----------|-------|--------| | JW-500 | [Dopamine receptor](/proteins/dopamine-receptor) agonist | Phase 2 | Recruiting | | JW-301 | [MAO-B](/enzymes/mao-b-inhibitor) inhibitor | Preclinical | Research | | JW-703 | [Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitor | Discovery | Early research |
JW-500 (Dopamine Agonist)
JW-500 is the company's lead Parkinson's disease program in Phase 2 clinical trials: